ADX 103

Drug Profile

ADX 103

Alternative Names: ADX-103

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aldeyra Therapeutics
  • Class
  • Mechanism of Action Aldehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes

Most Recent Events

  • 30 Mar 2017 Aldeyra Therapeutics plans a phase IIa trial in Dry eyes
  • 01 Jan 2017 Preclinical trials in Dry eyes in USA (Ophthalmic)
  • 31 Dec 2016 Aldeyra Therapeutics has patent protection for ADX 103 (Aldeyra Therapeutics, Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top